Immunocore Limited presented data from the IMCgp100-102 trial at the American Society of Clinical Oncology meeting that showed a durable response and strong overall survival rate in patients with metastatic uveal melanoma.
IMCgp100 is a bispecific biologic T-cell redirection therapy that targets the melanoma-associated antigen gp100, according to a company press release. Patients in the phase 1 portion of the phase 1/2 trial received the therapy on a weekly basis with an intrapatient escalation dosing regimen. The trial included 19 patients with metastatic uveal melanoma, and 17 were evaluated for efficacy.
Treatment with the therapy was associated with an objective response rate of 18% and a 1-year survival rate of 74%, according to the trial data.
About 150 patients will be enrolled in the phase 2 portion of the trial, with enrollment expected to be completed by September 2019.
There were no adverse events linked with IMCgp100 that resulted in discontinuation or death. Common adverse events included pruritus, pyrexia and fatigue, and hypotension.